Express Mail No. EV529783311US

Approved for use through 03/31/2006. OMB 0651-0032. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	COMPOUNDS AND METHODS FOR TREATING CANCER AND INFLAMMATION			
As the below named inventor(s), I/we declare that: This declaration is directed to: The attached application, or Application No. 10/520,250, U.S. National Phase of PCT/CA03/000975 filed June 25, 2003, as amended on (if applicable);				
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;				
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;				
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.				
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.				
FULL NAME OF INVENTOR(S)				
Inventor one: Zail	nui Zhang	Citizen of:	Canada	
Signature:	i ely	Date:	Oct 14, 2005	
Inventor two: Dav	rid L. Charest	Citizen of:	Canada	
Signature:		Date:		
Inventor three: Jun	Yan	Citizen of:	Canada	
Signature:		Date:		
Additional inventors or a legal representative are being named on additional form(s) attached hereto.				

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No. 540057.414USPC



Approved for use through 03/31/2006. OMB 0651-0032.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	COMPOUNDS AND METHODS FINFLAMMATION	OR TREAT	ING CANCER AND	
As the below named inventor(s), I/we declare that: This declaration is directed to: The attached application, or Application No. 10/520,250, U.S. National Phase of PCT/CA03/000975 filed June 25, 2003, as amended on (if applicable);				
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;				
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;				
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.				
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.				
FULL NAME OF INVENTOR(S)				
Inventor one: Zait	nui Zhang	Citizen of:	Canada	
Signature:		Date:		
Inventor two: Day	rid L. Charest	Citizen of:	Canada	
Signature:	A Dood (Jaren)	Date:	Softenber 19/05	
Inventor three: Jun	Yan	Citizen of:	Canada	
Signature:	n ya	Date:	Sept. 28, 2005	
Additional inventors or a legal representative are being named on additional form(s) attached hereto.				

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/96 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, 'no persons are required to respond to a collection of information unless it displays a valid OMB control number.

•	STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner	Zaihui Zhang et al.		
Application No:	10/520,250, U.S. National Phase of PCT/CA03/000975 filed June 25, 2003		
Entitled: COMPOUN INFLAMMA	IDS AND METHODS FOR TREATING CANCER AND		
QLT Inc	corporation		
(Name of Assi	gnee) a <u>corporation</u> (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)		
1. In the assignee of the	e entire right, title, and interest; or		
_	s than the entire right, title and interest.		
	centage) of its ownership interest is%		
	patent identified above by virtue of either:		
A. An assignment fro	m the inventor(s) of the patent application/patent identified above. as recorded in the United States Patent and Trademark Office at e, or for which a copy thereof is attached.		
B. A chain of title from current assignee a	n the inventor(s), of the patent application/patent identified above, to the s shown below:		
1. From:	То:		
The document w	ras recorded in the United States Patent and Trademark Office at me, or for which a copy thereof is attached.		
2. From:	То:		
	ras recorded in the United States Patent and Trademark Office at me, or for which a copy thereof is attached.		
3. From:	То:		
	ras recorded in the United States Patent and Trademark Office at me, or for which a copy thereof is attached.		
Additional docum	nents in the chain of title are listed on a supplemental sheet.		
Copies of assignment attached.	ents or other documents in the chain of title noted in B above are		
[NOTE: A separate copy (i. submitted to Assignment Direcords of the USPTO. See	e., the original assignment document or a true copy of the original document) must be vision in accordance with 37 CFR Part 3, if the assignment is to be recorded in the MPEP 302.8]		
The undersigned (whose	title is supplied below) is authorized to act on behalf of the assignee.		
001.18,2	-005 Jennifer Kaufman-Shaul		
Oct. 18, 2			
(604) 7 9 7- Telephone Nur	7519 Grennfur Kangfman-Shart Signature Chief Patent Counsel Title		
	Chief Patent Counsel		
	Title		

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Attorney Docket No.: 540057.414USPC

Application No. 10/520,250

COPY

ASSIGNMENT



THIS ASSIGNMENT, by

Zaihui Zhang, having a mailing address of: 4038 MacDonald Street, Vancouver, British Columbia, Canada V6L 2N9;

David L. Charest, having a mailing address of: 4640 West 15th Avenue, Vancouver, British Columbia, Canada V6R 3B6; and

Jun Yan, having a mailing address of: 819 Alderson Avenue, Coquitlam, British Columbia, Canada V3K 1V3;

(hereinafter referred to as the ASSIGNORS), witnesseth:

WHEREAS, said ASSIGNORS have invented certain new and useful improvements in COMPOUNDS AND METHODS FOR TREATING CANCER AND INFLAMMATION, set forth in an application for Letters Patent of the United States filed and assigned Application Serial No. 10/520,250. This application is a national stage application filed under 35 U.S.C. 371 of International Application No. PCT/CA03/000975, accorded an International Filing Date of June 25, 2003; which claims the benefit of U.S. Provisional Patent application No. 60/393,700 filed July 2, 2002; and

WHEREAS, QLT Inc., a corporation duly organized under and pursuant to the laws of the Province of British Columbia and having its principal place of business at 887 Great Northern Way, Vancouver, British Columbia V5T 4T5 Canada (hereinafter referred to as the ASSIGNEE) is desirous of acquiring the ASSIGNORS' entire right, title and interest in and to said invention and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient considerations, the receipt of which is hereby acknowledged, said ASSIGNORS have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto said ASSIGNEE, its successors, legal representatives and assigns, their entire right, title and interest in and to the above-mentioned invention, application for Letters Patent and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations and continuations-in-part of said applications, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treat or otherwise, said invention, application and all Letters Patent on said invention to be held and enjoyed by said ASSIGNEE, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the ASSIGNORS, had this sale and assignment not been made.

AND for the same consideration, said ASSIGNORS hereby covenant and agree to and with said ASSIGNEE, its successors, legal representatives and assigns, that, at the time of execution and delivery of

Page 1 of 4

540057.414USPC: 1005100 assignment to QLT Inc.doc

Attorney Docket No.: 540057.414USPC
Application No. 10/520,250

these presents, said ASSIGNORS are the sole and lawful owners of their entire right, title and interest in and to said inventions and applications, above-mentioned, and that the same are unencumbered and that said ASSIGNORS have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, said ASSIGNORS hereby covenant and agree to and with said ASSIGNEE, its successors, legal representatives and assigns, that said ASSIGNORS will, whenever counsel of said ASSIGNEE, or the counsel of its successor, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said applications, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said ASSIGNEE, its successors, legal representatives and assigns, but at the cost and expense of said ASSIGNEE, its successors, legal representatives and assigns.

AND said ASSIGNORS hereby request the Commissioner of Patents to issue said Letters Patent of the United States to said ASSIGNEE as the ASSIGNEE of said inventions and the Letters Patent to be issued thereon for the sole use of said ASSIGNEE, its successors, legal representatives and assigns.

This Assignment is effective as of June 25, 2003.

Date

Zaihui Zhang

I do hereby certify that Zaihui Zhang

who is personally known to me/or proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to this instrument.

did appear before me and sign this instrument and did statutorily declare before me upon oath that he executed the same in my presence for the uses and purposes therein expressed.

Signature of N

Printed Name

KAREN G. CORRAINI
BARRISTER & SOLICITOR

My appointment does not expire

Attorney Docket No.: 540057.414USPC

Application No. 10/520,250

Date David L. Charest

I do hereby certify that David L. Charest

who is personally known to me/or proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to this instrument,

did appear before me and sign this instrument and did statutorily declare before me upon oath that he executed the same in my presence for the uses and purposes therein expressed.

Signature of Notary Public MARY ANNE RICHTER

Barrister and Solicitor
310 - 5887 YEW STREET

Printed Name VANCOUVER, B.C. V6M 3Y2

304-264-1110

My appointment does not expire

Attorney Docket No.: 540057.414USPC Application No. 10/520,250

I do hereby certify that Jun Yan

who is personally known to me/or proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to this instrument,

did appear before me and sign this instrument and did statutorily declare before me upon oath that he executed the same in my presence for the uses and purposes therein expressed.

DORI C. ASSALY
Barrister & Solicitor

Printed NamBLAKE, CASSELS & GRAYDON LLP Sulte 2600, Three Bentall Centre 595 Burrard St., P.O. Box 49314 My appointment duascot expire V7X 1L3 (604) 631-3384